nach oben

16.09.2024 | Originalien

Sarkoidose

verfasst von: Prof. Dr. Raoul Bergner

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Sarkoidose ist in Nordeuropa die häufigste granulomatöse Erkrankung. Man unterscheidet zwischen akuten Formen der Sarkoidose und der chronischen Sarkoidose. Die chronische Sarkoidose kann nahezu alle Organe betreffen, wobei die Lunge mit 90–95 % am häufigsten betroffen ist. Das klinische Erscheinungsbild variiert zwischen asymptomatischen bzw. oligosymptomatischen Verläufen, die eher zufällig diagnostiziert werden, bis hin zu Verläufen mit akutem Organversagen. Eine umfangreiche Organdiagnostik ist bei Erstdiagnose erforderlich, um das Ausmaß des Organbefalls zu erfassen und daran angepasst Therapieentscheidungen zu treffen. Während asymptomatische Verläufe mit reiner pulmonaler Sarkoidose keiner Therapie bedürfen und im Verlauf beobachtet werden können, erfordern Verläufe mit umfangreicher Organbeteiligung oder Einschränkung einer Organfunktion eine Therapie. Die Therapie besteht in erster Linie aus der Gabe von Glukokortikoiden, bei unzureichender Wirkung oder Nebenwirkungen können verschiedene Immunsuppressiva bis hin zu Biologika ergänzt werden.

Arkema EV, Grunewald J, Kullberg S et al (2016) Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J 48:1690–1699. https://doi.org/10.1183/13993003.00477-2016CrossRefPubMed

Dumas O, Abramovitz L, Wiley AS et al (2016) Epidemiology of sarcoidosis in a prospective cohort study of U.S. Women. Ann Am Thorac Soc 13:67–71. https://doi.org/10.1513/AnnalsATS.201508-568BCCrossRefPubMedPubMedCentral

Hillerdal G, Nöu E, Osterman K, Schmekel B (1984) Sarcoidosis: epidemiology and prognosis. Am Rev Respir Dis 130:29–32. https://doi.org/10.1164/arrd.1984.130.1.29CrossRefPubMed

Milman N, Selroos O (1990) Pulmonary sarcoidosis in the Nordic countries 1950–1982. Epidemiology and clinical picture. Sarcoidosis 7:50–57PubMed

Pietinalho A, Hiraga Y, Hosoda Y et al (1995) The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis 12:61–67PubMed

Ungprasert P, Carmona EM, Utz JP et al (2016) Epidemiology of Sarcoidosis 1946–2013: a population-based study. Mayo Clin Proc 91:183–188. https://doi.org/10.1016/j.mayocp.2015.10.024CrossRefPubMed

Jeon MH, Kang T, Yoo SH et al (2020) The incidence, comorbidity and mortality of sarcoidosis in korea, 2008–2015: a nationwide population-based study. Sarcoidosis Vasc Diffuse Lung Dis 37:24–36. https://doi.org/10.36141/svdld.v37i1.7660CrossRefPubMedPubMedCentral

Yoon HY, Kim HM, Kim YJ, Song JW (2018) Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based study. Respir Res. https://doi.org/10.1186/s12931-018-0871-3CrossRefPubMedPubMedCentral

Baughman RP, Teirstein AS, Judson MA et al (2001) Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164:1885–1889. https://doi.org/10.1164/ajrccm.164.10.2104046CrossRefPubMed

10.

Bergner R, Weiner SM, Kehl G, de Groot K, Tielke S, Asendorf T, Korsten P (2023) Renal disease in sarcoidosis patients in a German multicentric retrospective cohort study. Respir Med 209:107121. https://doi.org/10.1016/j.rmed.2023.107121CrossRefPubMed

11.

Drent M, Crouser ED, Grunewald J (2021) Challenges of Sarcoidosis and its management. N Engl J Med 385:1018–1032. https://doi.org/10.1056/nejmra2101555CrossRefPubMed

12.

Crouser ED (2018) Role of imbalance between Th17 and regulatory T‑cells in sarcoidosis. Curr Opin Pulm Med 24:521–526. https://doi.org/10.1097/MCP.0000000000000498CrossRefPubMed

13.

Crouser ED, Maier LA, Baughman RP et al (2020) Diagnosis and detection of Sarcoidosis an official American thoracic society clinical practice guideline. Am J Respir Crit Care Med 201:E26–E51. https://doi.org/10.1164/RCCM.202002-0251STCrossRefPubMedPubMedCentral

14.

Ehrenstein B, Brochhausen C (2017) Differenzialdiagnose granulomatöser Erkrankungen. Z Rheumatol 76:415–424. https://doi.org/10.1007/s00393-017-0312-6CrossRefPubMed

15.

Gilbert S, Steinbrech DS, Landas SK, Hunninghake GW (1993) Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease. Am Rev Respir Dis 148:483–486. https://doi.org/10.1164/ajrccm/148.2.483CrossRefPubMed

16.

Tomita H, Ina Y, Sugiura Y et al (1997) Polymorphism in the Angiotensin-Converting Enzyme (ACE) Gene and Sarcoidosis. Am J Respir Crit Care Med 156:255–259CrossRefPubMed

17.

Vorselaars ADM, Van Moorsel CHM, Zanen P et al (2015) ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy. Respir Med 109:279–285. https://doi.org/10.1016/j.rmed.2014.11.009CrossRefPubMed

18.

Damoiseaux J (2020) The IL-2—IL‑2 receptor pathway in health and disease: The role of the soluble IL‑2 receptor. Clin Immunol. https://doi.org/10.1016/j.clim.2020.108515CrossRefPubMed

19.

Miyoshi S, Hamada H, Kadowaki T et al (2010) Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest 137:1391–1397. https://doi.org/10.1378/chest.09-1975CrossRefPubMed

20.

Eurelings LEM, Miedema JR, Dalm VASH et al (2019) Sensitivity and specificity of serum soluble interleukin‑2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. PLoS ONE. https://doi.org/10.1371/journal.pone.0223897CrossRefPubMedPubMedCentral

21.

Miyata J, Ogawa T, Tagami Y et al (2020) Serum soluble interleukin‑2 receptor level is a predictive marker for EBUS-TBNA-based diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 37:8–16. https://doi.org/10.36141/svdld.v37i1.8313CrossRefPubMedPubMedCentral

22.

Judson MA (2007) Extrapulmonary sarcoidosis. Semin Respir Crit Care Med 28:83–101. https://doi.org/10.1055/s-2007-970335CrossRefPubMed

23.

Mañá J, Rubio-Rivas M, Villalba N et al (2017) Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis. Medicine 96:e7595. https://doi.org/10.1097/MD.0000000000007595CrossRefPubMedPubMedCentral

24.

Ohara K, Judson MA, Baughman RP (2005) Clinical aspects of ocular sarcoidosis. Eur Respir Monogr. https://doi.org/10.1183/1025448x.00032012CrossRef

25.

Te HS, Perlman DM, Shenoy C et al (2020) Clinical characteristics and organ system involvement in sarcoidosis : comparison of the University of Minnesota Cohort with other cohorts. BMC Pulm Med. https://doi.org/10.1186/s12890-020-01191-xCrossRefPubMedPubMedCentral

26.

Terushkin V, Stern BJ, Judson MA et al (2010) Neurosarcoidosis: presentations and management. Neurologist 16:2–15. https://doi.org/10.1097/NRL.0b013e3181c92a72CrossRefPubMed

27.

Scadding JC (1961) Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J 2:1165–1172. https://doi.org/10.1136/bmj.2.5261.1165CrossRefPubMedPubMedCentral

28.

Nunes H, Brillet PY, Valeyre D et al (2007) Imaging in sarcoidosis. Semin Respir Crit Care Med 28:102–120. https://doi.org/10.1055/s-2007-970336CrossRefPubMed

29.

Mañá J, Marcoval J, Rubio M et al (2013) Granulomatous cutaneous sarcoidosis: diagnosis, relationship to systemic disease, prognosis and treatment. Sarcoidosis Vasc Diffuse Lung Dis 30:268–281PubMed

30.

Ungprasert P, Wetter DA, Crowson CS, Matteson EL (2016) Epidemiology of cutaneous sarcoidosis, 1976–2013: a population-based study from Olmsted County, Minnesota. J Eur Acad Dermatology Venereol 30:1799–1804. https://doi.org/10.1111/jdv.13760CrossRef

31.

Jamilloux Y, Kodjikian L, Broussolle C, Sève P (2014) Sarcoidosis and uveitis. Autoimmun Rev 13:840–849. https://doi.org/10.1016/J.AUTREV.2014.04.001CrossRefPubMed

32.

Bergner R, Löffler C (2018) Renal sarcoidosis: approach to diagnosis and management. Curr Opin Pulm Med 24:513–520. https://doi.org/10.1097/MCP.0000000000000504CrossRefPubMed

33.

Mahévas M, Lescure FX, Boffa JJ et al (2009) Renal sarcoidosis: clinical, laboratory, and histologic presentation and utcome in 47 patients. Medicine 88:98–106. https://doi.org/10.1097/MD.0b013e31819de50fCrossRefPubMed

34.

Schupp JC, Freitag-Wolf S, Bargagli E et al (2018) Phenotypes of organ involvement in sarcoidosis. Eur Respir J 51:1–11. https://doi.org/10.1183/13993003.00991-2017CrossRef

35.

Kandolin R, Lehtonen J, Airaksinen J et al (2015) Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 131:624–632. https://doi.org/10.1161/CIRCULATIONAHA.114.011522CrossRefPubMed

36.

Skowasch D, Gaertner F, Marx N et al (2020) Diagnostics and treatment of cardiac Sarcoidosis: consensus paper of the German respiratory society (DGP) and the German cardiac society (DGK). Pneumologie 74:24–34. https://doi.org/10.1055/a-1031-4588CrossRefPubMed

37.

Smedema J, Nt MMEDI, Sa FCP et al (2005) Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac Sarcoidosis. J Am Coll Cardiol 45:1683–1690. https://doi.org/10.1016/j.jacc.2005.01.047CrossRefPubMed

38.

Ardehali H, Howard DL, Hariri A et al (2005) A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 150:459–463. https://doi.org/10.1016/j.ahj.2004.10.006CrossRefPubMed

39.

Korsten P, Chehab G (2017) Muskuloskelettale Manifestationen der Sarkoidose. Z Rheumatol 76:408–414. https://doi.org/10.1007/s00393-017-0313-5CrossRefPubMed

40.

American Thoracic Society (1999) Statement on Sarcoidosis; ATS/ERS/WASGOG. Am J Resp Crit Care Med 160:736–755CrossRef

41.

Baughman RP, Valeyre D, Korsten P et al (2021) ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. https://doi.org/10.1183/13993003.04079-2020CrossRefPubMed

42.

Paramothayan NS, Lasserson TJ, Jones P (2005) Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001114.pub2CrossRefPubMedPubMedCentral

43.

Nozaki K, Judson MA (2012) Neurosarcoidosis: Clinical manifestations, diagnosis and treatment. Presse Med 41:e331–e348. https://doi.org/10.1016/j.lpm.2011.12.017CrossRefPubMed

44.

Hilderson I, Van Laecke S, Wauters A, Donck J (2014) Treatment of renal sarcoidosis: Is there a guideline? Overview of the different treatment options. Nephrol Dial Transplant 29:1841–1847. https://doi.org/10.1093/ndt/gft442CrossRefPubMed

45.

Baughman RP, Lower EE (2015) Treatment of Sarcoidosis. Clin Rev Allergy Immunol 49:79–92. https://doi.org/10.1007/s12016-015-8492-9CrossRefPubMed

46.

Broos CE, Poell LHC, Looman CWN et al (2018) No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. Respir Med 138:S31–S37. https://doi.org/10.1016/j.rmed.2017.10.022CrossRef

47.

Baughman RP, Winget DB, Lower EE (2000) Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffus Lung Dis 17:60–66

48.

Vorselaars ADM, Wuyts WA, Vorselaars VMM et al (2013) Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 144:805–812. https://doi.org/10.1378/chest.12-1728CrossRefPubMed

49.

Fang C, Zhang Q, Wang N et al (2019) Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study. Sarcoidosis Vasc Diffuse Lung Dis 36:217–227. https://doi.org/10.36141/svdld.v36i3.8449CrossRefPubMedPubMedCentral

50.

Gavrysyuk V, Merenkova I, Dziublyk Y et al (2021) Efficacy and tolerability of methotrexate and methylprednisolone in a comparative assessment of the primary and long-term outcomes in patients with pulmonary sarcoidosis. Diagnostics. https://doi.org/10.3390/diagnostics11071289CrossRefPubMedPubMedCentral

51.

Kahlmann V, Janssen Bonás M, Moor CC et al (2020) Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study. BMC Pulm Med 20:271. https://doi.org/10.1186/s12890-020-01290-9CrossRefPubMedPubMedCentral

52.

Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C et al (2017) Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Semin Arthritis Rheum 47:288–294. https://doi.org/10.1016/j.semarthrit.2017.03.005CrossRefPubMed

53.

Baughman RP, Drent M, Kavuru M et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174:795–802. https://doi.org/10.1164/rccm.200603-402OCCrossRefPubMed

54.

Judson MA, Baughman RP, Costabel U et al (2008) Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 31:1189–1196. https://doi.org/10.1183/09031936.00051907CrossRefPubMed

55.

Rossman MD, Newman LS, Baughman RP et al (2006) A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23:201–208PubMed

56.

Sweiss NJ, Lower EE, Mirsaeidi M et al (2014) Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 43:1525–1528. https://doi.org/10.1183/09031936.00224513CrossRefPubMedPubMedCentral

57.

Damsky W, Wang A, Kim DJ et al (2022) Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat Commun. https://doi.org/10.1038/s41467-022-30615-xCrossRefPubMedPubMedCentral

58.

Friedman MA, Le B, Stevens J et al (2021) Tofacitinib as a steroid-sparing therapy in pulmonary Sarcoidosis, an open-label prospective proof-of-concept study. Am J Physiol 199:147–153. https://doi.org/10.1007/s00408-021-00436-8CrossRef

59.

Nozaki K, Judson MA (2013) Neurosarcoidosis. Curr Treat Options Neurol 15:492–504. https://doi.org/10.1007/s11940-013-0242-9CrossRefPubMed

60.

Bechman K, Christidis D, Walsh S et al (2018) A review of the musculoskeletal manifestations of sarcoidosis. Rheumatology 57:777–783. https://doi.org/10.1093/rheumatology/kex317CrossRefPubMed

61.

Sweiss NJ, Patterson K, Sawaqed R et al (2010) Rheumatologic manifestations of Sarcoidosis. Semin Respir Crit Care Med 31:463–473CrossRefPubMedPubMedCentral

Titel: Sarkoidose
verfasst von: Prof. Dr. Raoul Bergner
Publikationsdatum: 16.09.2024
Verlag: Springer Vienna
Erschienen in: Rheuma Plus / Schweiz
Print ISSN: 3004-9253
Elektronische ISSN: 3004-8931
DOI: https://doi.org/10.1007/s44332-024-00027-8

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten